IOVANCE BIOTHERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IOVA in the last 30 days.
See all $IOVA insider activity →Iovance Biotherapeutics updated its corporate presentation, affirming 2026 revenue guidance of $410M–$420M, up ~15% from prior estimates. The company reported 2Q26 revenue of ~$99M, a 66% YoY increase for Amtagvi, with ~$304M in cash as of 6/30/26 and a 56% gross margin. It has ~100 Authorized Treatment Centers and capacity for 5K annual patients.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of I
Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning IOVA (IOVANCE BIOTHERAPEUTICS, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent IOVA coverage spans market movers, financial news and earnings.
No new information; likely no immediate price move.
Guidance may be viewed as modest relative to prior expectations.
Guidance raise and strong price move suggest upside pressure.
Revenue outlook raise fuels bullish sentiment.
Guidance beat drives strong upside momentum.
AlphAI scores every news story that mentions IOVA with an AI model for sentiment and relevance, and aggregates insider trades from IOVANCE BIOTHERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Iovance Biotherapeutics updated its corporate presentation, affirming 2026 revenue guidance of $410M–$420M, up ~15% from prior estimates. The company reported 2Q26 revenue of ~$99M, a 66% YoY increase for Amtagvi, with ~$304M in cash as of 6/30/26 and a 56% gross margin. It has ~100 Authorized Treatment Centers and capacity for 5K annual patients.
1 min readIOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of I
2 min readSeveral biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.
2 min readCapricor Therapeutics (CAPR) shares rose 17% after positive clinical data. Iovance Biotherapeutics (IOVA) gained 31% on raised revenue outlook. DraftKings (DKNG) fell 7% amid competitor funding news. Trade Desk (TTD) declined on revenue growth concerns. Dow is down for Q3, while S&P 500 and Nasdaq are up. PCE data release expected to impact markets.
2 min readIovance (IOVA) surged 31% to a 2-year high after raising its 2026 revenue outlook to $410M-$420M, exceeding consensus. AbCellera (ABCL) gained 6% with JPMorgan initiating coverage with an 'Overweight' rating and $17 target. CrowdStrike (CRWD) rose 1% after announcing plans to integrate with OpenAI's marketplace. Retail sentiment improved for IOVA and ABCL but remained bearish for CRWD.
2 min readMajor U.S. indices closed lower on Tuesday. Fair Isaac (FICO) fell 26.52% after FHFA announced mortgage pricing changes. Iovance (IOVA) rose 31.48% on raised 2026 revenue guidance. Stablecoin Development (SDEV) surged 108.28% on heavy trading volume. Carnival (CCL) gained 13.41% on strong Q3 results. Micron (MU) rose 1.05% ahead of earnings report.
3 min readIovance Biotherapeutics (IOVA) downgraded to Hold as its stock rally has priced in future success. FY26 revenue guidance raised to $410–$420M, with gross margins at 56%. Analysts see limited upside potential beyond current valuation.
1 min readBiotech stocks SLXN, SMMT, IOVA, NTHI rose on Sept 29, 2026, due to positive developments. SLXN surged 30% after preclinical data. SMMT gained 6% from AstraZeneca's $2.0B investment. IOVA rose 34% on raised revenue guidance. NTHI increased 7.59% ahead of FDA meeting.
2 min readCarnival rose 12% after reporting strong Q3 earnings and bookings. Iovance Biotherapeutics surged 26% on raised revenue guidance. Bloom Energy jumped 13% following a price target increase and expansion news. Fair Isaac plunged 18% due to mortgage pricing changes. Other movers include Oracle, Bloomin' Brands, SpaceX, Summit Therapeutics, and CarMax.
3 min readKodiak Sciences (KOD) surged 177% to a 52-week high after positive Phase 3 trial results for its retinal disease drug. Grail (GRAL) rose 4% following FDA panel support for its cancer detection test. Iovance (IOVA) gained 7% after raising revenue guidance. Repligen (RGEN) climbed 2% with 12% revenue growth reported.
2 min read
